The role and clinical research progress of IL-23 protein in chronic inflammatory diseases

1. Molecular Characteristics and Cellular Sources of IL-23 Protein

IL-23 protein is a key pro-inflammatory cytokine that plays a crucial role in the development of chronic inflammatory diseases. This protein is primarily produced by activated antigen-presenting cells such as dendritic cells, macrophages, and monocytes. As a member of the IL-12 cytokine family, IL-23 protein is a heterodimeric structure composed of p19 and p40 subunits. Its effects are mainly mediated by CD4-positive T helper cell subsets (Th17), unique γ/δ T cell subsets, natural killer T cell subsets, and type 3 innate lymphoid cells. Elevated levels of IL-23 protein are observed in the lesional tissues of patients with Crohn's disease, ulcerative colitis, and psoriasis, indicating its involvement in the pathological processes of these diseases.

2. Signal Transduction Mechanism of IL-23 Protein

IL-23 protein exerts its biological effects by binding to the IL-23 receptor complex on the cell surface. The IL-23 receptor complex consists of the IL-23 receptor and the IL-12 receptor β1 subunit, which are associated with JAK family members JAK2 and TYK2. The binding of IL-23 to its receptor promotes the activation of JAK kinases, leading to phosphorylation of tyrosine residues on both the JAK kinases and the cytoplasmic tails of the IL-23 receptor. These phosphorylated tyrosine residues create docking sites for STAT3 monomers, which bind via Src homology 2 domains. Activated JAK2 and TYK2 phosphorylate STAT3 monomers, resulting in STAT3 dimerization, nuclear translocation, and DNA binding to target gene promoters, thereby initiating downstream gene transcription. This signaling pathway is the core mechanism through which IL-23 protein exerts its pro-inflammatory functions.

3. Pathological Role of IL-23 Protein in Chronic Inflammation

Chronic inflammatory diseases are caused by uncontrolled immune responses that trigger excessive activation of signaling cascades, leading to the accumulation of pro-inflammatory mediators and ultimately clinical symptoms. The pathological consequences of excessive IL-23 protein signaling are closely related to its ability to promote the production of inflammatory mediators. This protein can induce target cells to produce pathogenic inflammatory mediators such as IL-17, IL-22, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-α. These mediators further promote the rapid recruitment and activation of granulocytes and macrophages, which are equipped with extensive effector tools capable of causing tissue damage that drives chronic inflammation and ultimately leads to clinical symptoms. Therefore, IL-23 protein occupies an upstream regulatory position in the pathogenesis of chronic inflammatory diseases.

4. Therapeutic Strategies Targeting IL-23 Protein and Clinical Research

Given the central role of IL-23 protein in chronic inflammatory diseases, the use of neutralizing antibodies to interfere with IL-23 signaling has shown promising therapeutic effects in various inflammatory conditions. Intervention strategies targeting IL-23 protein primarily focus on its p19 subunit, using specific antibodies to block the binding of IL-23 to its receptor, thereby inhibiting the activation of downstream signaling pathways. The advantage of this approach lies in its specificity for blocking IL-23 signaling without affecting the functions of other p40-dependent cytokines such as IL-12, enabling precise modulation. Compared to strategies targeting more downstream inflammatory mediators, targeting IL-23 protein may provide more upstream and broader control of inflammation.

Antibody drugs targeting IL-23 protein have been investigated in clinical studies for various chronic inflammatory diseases. In patients with ulcerative colitis, the first participant has been dosed in a phase 2 clinical study of an anti-IL-23 antibody. Previous research has demonstrated the therapeutic value of blocking IL-23 signaling in chronic inflammatory diseases such as Crohn's disease, ulcerative colitis, and psoriasis. Preclinical studies and early clinical trial results indicate that intervention strategies targeting IL-23 protein can effectively control disease activity, improve patient symptoms, and exhibit favorable safety profiles. These positive findings have accelerated the clinical development of IL-23-targeted drugs in the treatment of chronic inflammatory diseases.

5. Research Significance and Future Perspectives

As a key molecule linking innate and adaptive immunity, IL-23 protein plays a central role in the maintenance and amplification of chronic inflammation. Through the activation of the JAK-STAT signaling pathway, this protein induces the production of multiple pro-inflammatory mediators, promotes the recruitment and activation of immune cells, and ultimately leads to tissue damage and clinical symptoms. A deep understanding of the biological functions of IL-23 protein provides a theoretical foundation for developing therapeutic strategies targeting this signaling pathway. Currently, anti-IL-23 antibodies have entered clinical research stages for chronic inflammatory diseases such as ulcerative colitis, with preliminary results showing promising applications. Future research will further explore the specific mechanisms of IL-23 protein in different chronic inflammatory diseases, optimize IL-23-targeted intervention strategies, evaluate their long-term safety and efficacy, and investigate their potential for combination with other therapeutic approaches. As our understanding of the IL-23 protein signaling network continues to deepen, its application value in the treatment of chronic inflammatory diseases will continue to expand.

6. Which Companies Provide IL-23 Protein?

Nanjing UA-Biotech Co., Ltd. (UA-Bio) has independently developed "IL-23 Protein, Human", a high-quality recombinant protein reagent specifically designed for research on Th17-type immune responses, autoimmune diseases, and inflammatory mechanisms. This protein is human interleukin-23 (IL-23), a heterodimeric cytokine composed of p19 and p40 subunits that efficiently activates the IL-23 receptor signaling pathway, promotes Th17 cell differentiation, maintains their pathogenic functions, and induces the production of IL-17 family cytokines. It provides a stable and reliable standardized tool for constructing autoimmune disease models, exploring inflammatory mechanisms, and developing drugs.

Nanjing UA-Biotech Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding "IL-23 Protein, Human" (Catalog No.: UA040207), please feel free to contact us.